Autocrine NGFβ/TRKA signalling is an important survival factor for Hodgkin lymphoma derived cell lines

Leukemia Research

Volumn 32, Issue 1, 2008, Pages 163-167

  Renné, Christoph ^a   Minner, Sarah ^a   Küppers, Ralf ^b   Hansmann, Martin Leo ^a   Bräuninger, Andreas ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

AKT; Hodgkin lymphoma; K 252a; NGFb; Receptor tyrosine kinase; TRKA

Indexed keywords

K 252A; LIGAND; NERVE GROWTH FACTOR BETA SUBUNIT; PROTEIN TYROSINE KINASE A; CARBAZOLE DERIVATIVE; INDOLE ALKALOID; K 252; NERVE GROWTH FACTOR; NGFB PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ARTICLE; AUTOCRINE EFFECT; B LYMPHOCYTE; CELL CULTURE; CELL LINE; CELL SURVIVAL; CONTROLLED STUDY; CULTURE MEDIUM; ENZYME ACTIVATION; ENZYME INHIBITION; GENE DOSAGE; HODGKIN DISEASE; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; FLUORESCENCE IN SITU HYBRIDIZATION; METABOLISM; TUMOR CELL LINE;

B-LYMPHOCYTES; CARBAZOLES; CELL LINE, TUMOR; HODGKIN DISEASE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; INDOLE ALKALOIDS; NERVE GROWTH FACTOR; RECEPTOR, TRKA; SIGNAL TRANSDUCTION;

EID: 36049049415     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2007.05.019     Document Type: Article

References (8)

1. Renné C., Willenbrock K., Küppers R., Hansmann M.L., and Bräuninger A. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood 105 (2005) 4051-4059
2. Torcia M., Bracci-Laudiero L., Lucibello M., et al. Nerve growth factor is an autocrine survival factor for memory B lymphocytes. Cell 85 (1996) 345-356
3. Martin-Subero J.I., Harder L., Gesk S., et al. Interphase FISH assays for the detection of translocations with breakpoints in immunoglobulin light chain loci. Int J Cancer 98 (2002) 470-474
4. Ruggeri B.A., Miknyoczki S.J., Singh J., and Hudkins R.L. Role of neurotrophin-trk interactions in oncology: the anti-tumor efficacy of potent and selective trk tyrosine kinase inhibitors in pre-clinical tumor models. Curr Med Chem 6 (1999) 845-857
5. Zhou B.P., and Hung M.C. Dysregulation of cellular signaling by HER2/neu in breast cancer. Semin Oncol 30 (2003) 38-48
6. Renné C., Willenbrock K., Martin-Subero J.I., et al. High expression of several tyrosine kinases and activation of the PI3K/AKT pathway in mediastinal large B cell lymphoma reveals further similarities to Hodgkin lymphoma. Leukemia 21 (2007) 780-787
7. Kase H., Iwahashi K., Nakanishi S., et al. K-252 compounds, novel and potent inhibitors of protein kinase C and cyclic nucleotide-dependent protein kinases. Biochem Biophys Res Commun 142 (1987) 436-440
8. Undevia S.D., Vogelzang N.J., Mauer A.M., Janisch L., Mani S., and Ratain M.J. Phase I clinical trial of CEP-2563 dihydrochloride, a receptor tyrosine kinase inhibitor, in patients with refractory solid tumors. Invest New Drugs 22 (2004) 449-458